Opinion|Videos|December 28, 2023
Future Perspectives in KRAS G12C-Mutated NSCLC
Author(s)Joshua K. Sabari, MD, Edward B. Garon, MD, MS
In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape.
Advertisement
Episodes in this series
Advertisement
Related to this article
Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
2
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
3
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
4
Dr Forde on Selecting Neoadjuvant and Perioperative Immunotherapy in Resectable NSCLC
5